Hepatitis B Vaccination for Travellers

Research Review Educational Series E-Learning Module


Hepatitis B Vaccination for Travellers

This Research Review Educational Series E-Learning Module provides detailed insight into evidence-based information and guidance on hepatitis B vaccination for travellers. The module is primarily intended for healthcare professionals who provide pre-travel health advice, including GPs, travel doctors, practice nurses, specialist nurses, pharmacists, and those specialising in travel medicine. It may also be of interest to infectious disease physicians.

Before starting the module please read the Research Review Educational Series publication, accessed through the link below:

to access the quiz source material
Educational Series - Hepatitis B Vaccination for Travellers

The PDF through the link above can be viewed on screen, saved and printed.

This Educational Series E-Learning Module covers:

  • An overview of hepatitis B
  • Risk factors for hepatitis B infection amongst travellers
  • General pre-travel vaccination advice
  • Guidelines for pre-travel hepatitis B vaccination
  • Special groups for pre-travel hepatitis B vaccination
  • Pre-travel hepatitis B serological screening
  • Accelerated hepatitis B vaccination schedules

Learning outcomes

After completing this module you will improve your knowledge of:

  • How to identify travellers at risk of hepatitis B infection
  • Appropriate general pre-travel vaccination advice
  • Guidelines for pre-travel hepatitis B vaccination
  • How to manage special groups for pre-travel hepatitis B vaccination
  • Appropriate management of pre-travel hepatitis B serological screening and accelerated hepatitis B vaccination schedules

Contributing Experts

Expert commentary is provided by Dr Jenny Visser.  Jenny is a Senior Lecturer in Travel Medicine in the Department of Primary Health Care and General Practice, University of Otago, Wellington and works part time in clinical travel medicine at The Travel Doctor in Wellington.

Module questions have been developed by Dr Chris Tofieldwho works in primary care skin cancer treatment, is clinical advisor at Bay of Plenty District Health Board, and consultant to Research Review.


“Hepatitis B for Travellers" E-Learning Module has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.
Further info

"Hepatitis B for Travellers" E-Learning Module has been endorsed by The College of Nurses and has been approved for 1 hour professional development.
Further info


  • Anonymous. Hepatitis B fact sheet. Geneva: World Health Organization. Last update date: July 2016. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/. [Date accessed: 05/01/17].
  • Anonymous. Viral hepatitis - Hepatitis B information. Atlanta, GA: Centers for Disease Control and Prevention. Last update date: 31/05/15. Available from: https://www.cdc.gov/hepatitis/hbv/index.htm. [Date accessed: 03/01/17].
  • Schweitzer A, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.
  • Anonymous. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544.
  • Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78(2):169-77.
  • Chang MH, et al. Prevention of hepatitis B. Cold Spring Harb Perspect Med. 2015;5(3):a021493.
  • Anonymous. Immunisation handbook (3rd edition). Wellington: Ministry of Health. 2017. Available from: http://www.health.govt.nz/system/files/documents/publications/immunisation-handbook-2017-may17-v3.pdf.
  • Anonymous. Imunization summary. A statistical reference containing data through 2013. 2014. New York, NY: United Nations Children’s Fund (UNICEF). Available from: http://www.who.int/immunization/monitoring_surveillance/Immunization_Summary_2013.pdf?ua=1
  • Mann J, et al. Modelling the epidemiology of hepatitis B in New Zealand. J Theor Biol. 2011;269(1):266-72.
  • Anonymous. UNWTO tourism highlights, 2016 Edition. Madrid: World Tourism Organization (UNWTO); 2016. Available from: http://www.e-unwto.org/doi/pdf/10.18111/9789284418145. [Date accessed: 05/01/17].
  • Ott JJ, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-9.
  • Boggild AK, et al. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine. 2010;28(46):7389-95.
  • Johnson DF, et al. Hepatitis B and C infection in international travelers. J Travel Med. 2013;20(3):194-202.
  • Anonymous. International travel and migration: November 2016. Wellington: Statistics New Zealand; 21 December 2016. Available from: http://www.stats.govt.nz/browse_for_stats/population/Migration/IntTravelAndMigration_HOTPNov16.aspx
  • Milne A, et al. Prevalence of hepatitis B infections in a multiracial New Zealand community. N Z Med J. 1985;98(782):529-32.
  • Robinson T, et al. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. N Z Med J. 2005;118(1211):U1345.
  • Leggat PA, et al. Hepatitis B risks and immunisation coverage amongst Australians travelling to southeast Asia and east Asia. Travel Med Infect Dis. 2009;7(6):344-9.
  • Streeton CL, et al. Risk of exposure to hepatitis B and other blood-borne viruses among Australians who travel abroad. J Travel Med. 2006;13(6):345-50.
  • Sonder GJ. Hepatitis B vaccination in travelers. Expert Rev Vaccines. 2008;7(5):673-7.
  • Sonder GJ, et al. Risk of hepatitis B for travelers: is vaccination for all travelers really necessary? J Travel Med. 2009;16(1):18-22.
  • Zuckerman JN, et al. Hepatitis B immunisation in travellers: poor risk perception and inadequate protection. Travel Med Infect Dis. 2008;6(5):315-20.
  • Anonymous. Health and travel. Safetravel Official advice for New Zealanders living and travelling overseas. Wellington: Ministry of Foreign Affairs and Trade. Last update date: 09/12/13. Available from: https://safetravel.govt.nz/health-and-travel. [Date accessed: 04/01/17].
  • Anonymous. Medical tourism. Safetravel Official advice for New Zealanders living and travelling overseas. Wellington: Ministry of Foreign Affairs and Trade. Last update date: 31/03/16. Available from: https://safetravel.govt.nz/news/medical-tourism. [Date accessed: 04/01/17].
  • Anonymous. International travel and health (situation as on 1 January 2012). Poumerol G, et al. (eds). Geneva: World Health Organization. 2012. Available from: http://apps.who.int/bookorders/MDIbookPDF/Book/18000079.pdf.
  • Averhoff F. Traveler’s health. Chapter 3. Infectious diseases related to travel - Hepatitis B. Atlanta, GA: Centers for Disease Control and Prevention. Last update date: 31/10/16. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b. [Date accessed: 04/01/17].
  • Anonymous. Vaccination for international travel. Australian immunisation handbook, 10th Edition. Canberra, ACT: Australian Government Department of Health. Last update date: 30/08/16. Available from: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part3~handbook10-3-2#3-2-4. [Date accessed: 05/01/17].
  • Jong EC. Risks of hepatitis A and B in the traveling public. J Travel Med. 2001;8 Suppl 1:S3-8.
  • Joines RW, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 2001;19(32):4710-9.
  • Burgess MA, et al. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine. 2001;19(32):4835-41.
  • Connor BA, et al. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med. 2007;14(1):9-15.
  • Poovorawan K, et al. Hepatitis B vaccination for international travelers to Asia. Tropical Diseases, Travel Medicine and Vaccines. 2016;2(14).
  • Anonymous. Medical tourism. Going abroad for medical care. Travelers’s health. Atlanta: Centers for Disease Control and Prevention. Last update date.; Available from: https://www.cdc.gov/features/medicaltourism/index.html. [Date accessed: 18/01/17].
  • Babik JM, et al. Transplant tourism: understanding the risks. Curr Infect Dis Rep. 2015;17(4):473.
  • Anker AE, et al. Estimating the risks of acquiring a kidney abroad: a meta-analysis of complications following participation in transplant tourism. Clin Transplant. 2012;26(3):E232-41.
  • Bester R. Travellers visiting friends and relatives often unaware of risks. New Zealand Doctor Newspaper. Issue date: 26/10/16. Auckland: The Health Media.
  • Heywood AE, et al. The contribution of travellers visiting friends and relatives to notified infectious diseases in Australia: state-based enhanced surveillance. Epidemiol Infect. 2016:1-10.
  • Boggild AK, et al. Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011. Open Med. 2014;8(1):e20-32.
  • Bacaner N, et al. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA. 2004;291(23):2856-64.
  • Anonymous. Hepatitis B FAQs for health professionals. Viral hepatitis - Hepatitis B information. Atlanta, GA: Centers for Disease Information and Prevention. Last update date: 04/08/16. Available from: https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ. [Date accessed: 18/01/17].
  • Avdicova M, et al. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age. Vaccine. 2015;33(23):2727-33.
  • Bagheri-Jamebozorgi M, et al. The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy. Hum Vaccin Immunother. 2014;10(12):3731-6.
  • Behre U, et al. Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Hum Vaccin Immunother. 2016;12(11):2916-20.
  • Poovorawan Y, et al. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother. 2013;9(8):1679-84.
  • Van Herck K, et al. Travelers’ knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J Travel Med. 2003;10(2):75-8.
  • Marchou B, et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis. 1995;172(1):258-60.
  • Bock HL, et al. Accelerated Schedule for Hepatitis B Immunization. J Travel Med. 1995;2(4):213-7.
  • Nothdurft HD, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine. 2002;20 (7-8):1157-62.
  • Zuckerman J. The place of accelerated schedules for hepatitis A and B vaccinations. Drugs. 2003;63(17):1779-84.